Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

{
  "signal_id": "f4912b3c-b4cd-8de3-74b7-ca9d2e15bb0a",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-28T10:45:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html",
    "title": "Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial",
    "ticker": "NYSE:LLY",
    "excerpt": "In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks Participants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with Ozempic 2 mg at 80 weeks TRANSCEND-T2D-2 marks the sixth Phase 3 trial in which retatrutide has delivered powerful efficacy, reinforcing its potential to transform cardiometabolic care INDIANAPOLIS , Oct 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), the maker of Mounjaro (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes. At 80 weeks, retatrutide met the primary and all key secondary endpoints, delivering greater A1C reduction and substantially more weight loss than Ozempic. 1,2 Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health: \"Head-to-head trials show patients and physicians how a potential new medicine compares with treatments that are available and reimbursed today. In TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide with another incretin medicine, retatrutide delivered greater A1C reduction and more than double the weight loss of the highest approved dose of Ozempic for type 2 diabetes. Based on these results and those...",
    "product": "retatrutide",
    "summary": "Eli Lilly and Company announced positive topline results from the Phase 3 TRANSCEND-T2D-2 clinical trial evaluating retatrutide in adults with type 2 diabetes.",
    "location": "Indianapolis, Indiana, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA3042400&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "retatrutide",
      "full_text": "retatrutide",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-10-28T10:45:00Z",
    "location_data": [
      {
        "city": "Indianapolis",
        "state": "Indiana",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-28",
    "article_sentence": "Eli Lilly and Company (NYSE: LLY ), the maker of Mounjaro (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes."
  }
}

curl https://signals.autobound.ai/v1/signals/f4912b3c-b4cd-8de3-74b7-ca9d2e15bb0a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'